Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any inflammatory bowel disease in which the cause of the disease is a mutation in the IL10RB gene.
Features include always present findings: Rectovaginal fistula, Enterocolitis, Pancolitis, and Recurrent bronchitis and others; and common findings: Enterocutaneous fistula and Perianal abscess.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 1 | Recurrent bronchitis |
Age of onset: infancy.
IL10RB encodes interleukin 10 receptor subunit beta (325 aa). Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. Highest expression in Whole Blood (55.0 TPM) and Spleen (43.6 TPM).
Inflammatory bowel disease 25 is caused by mutations in the IL10RB gene on chromosome 21.
The IL10RB protein participates in IFNL2,IFNL3 bind IL10RB:TYK2 and IFNLR1:JAK1 pathway.
IL10RB is classified as a druggable target (Druggable Genome category) with score 8.7.
Genetic testing for IL10RB is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for inflammatory bowel disease 25 has been reported in the published literature.
Phenotype severity distribution: 5 always present features, 2 common features.
No clinical trials have been registered for inflammatory bowel disease 25.
213 publications have been identified in PubMed for inflammatory bowel disease 25. Kisho has analyzed 116 by research type. Research spans Review / Meta-Analysis (39%), Epidemiology / Natural History (29%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 45 | 39% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 6:50 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Disease patterns and progression |
34 |
29% |
Laboratory research | 19 | 16% |
Testing and diagnosis research | 7 | 6% |
Clinical study results | 6 | 5% |
Patient case studies | 3 | 3% |
Other research | 2 | 2% |
Kjærsgaard Andersen R (2026). [PMID: 41405899](https://pubmed.ncbi.nlm.nih.gov/41405899/). *JAMA Dermatol*. [Epidemiology / Natural History]
Abhari AP (2026). [PMID: 41540376](https://pubmed.ncbi.nlm.nih.gov/41540376/). *BMC Gastroenterol*. [Review / Meta-Analysis]
Xiao J (2026). [PMID: 41888292](https://pubmed.ncbi.nlm.nih.gov/41888292/). *Clin Rev Allergy Immunol*. [Review / Meta-Analysis]
Chapman C (2026). [PMID: 41760568](https://pubmed.ncbi.nlm.nih.gov/41760568/). *J Manag Care Spec Pharm*. [Review / Meta-Analysis]
Durak MB (2025). [PMID: 41340405](https://pubmed.ncbi.nlm.nih.gov/41340405/). *Turk J Gastroenterol*. [Epidemiology / Natural History]
Nakajima M (2025). [PMID: 40025407](https://pubmed.ncbi.nlm.nih.gov/40025407/). *J Med Ultrason (2001)*. [Review / Meta-Analysis]
Huang S (2025). [PMID: 40120774](https://pubmed.ncbi.nlm.nih.gov/40120774/). *Gastroenterology*. [Basic Science / Preclinical]
Baccarella A (2025). [PMID: 40378986](https://pubmed.ncbi.nlm.nih.gov/40378986/). *Clin Gastroenterol Hepatol*. [Clinical Trial Publication]
Tiles-Sar N (2025). [PMID: 40243391](https://pubmed.ncbi.nlm.nih.gov/40243391/). *Cochrane Database Syst Rev*. [Review / Meta-Analysis]
Ramineni M (2025). [PMID: 40258492](https://pubmed.ncbi.nlm.nih.gov/40258492/). *Lab Invest*. [Diagnostic / Biomarker]